Cancer presents medicine with a fundamental biological problem: two patients diagnosed with the same cancer may not, at the molecular level, have the same disease.
Their tumors can carry different mutations, produce different antigens and respond differently to treatment. Even within one patient, cancer can consist of multiple populations of cells that continue evolving.
Personalized cancer vaccines offer an opportunity to address this complexity by creating a treatment based on the molecular characteristics of an individual patient’s tumor.
The question is no longer simply: Which existing therapy best fits this cancer?
It is increasingly: Can we create a therapy specifically for the cancer growing inside this patient?
The Promise—and Challenge—of Neoantigens
Cancer cells accumulate mutations, some of which generate abnormal proteins containing neoantigens. Because these neoantigens are absent from healthy cells, they can provide highly specific targets for the immune system.
Tumor and normal tissue can be sequenced, mutations identified and candidate neoantigens predicted. A personalized vaccine can then encode selected tumor-specific targets to educate the patient’s immune system to recognize cancer cells carrying them.
But identifying mutations is relatively easy. Selecting the mutations capable of producing clinically meaningful antitumor immunity is much harder.
Only a fraction of computationally predicted neoantigens may generate effective immune responses. Their quality, presentation, clonality and immunogenicity can therefore matter more than simply maximizing the number incorporated into a vaccine.
This may be one of the most important unresolved challenges in personalized cancer vaccination.
Why Has Cancer Vaccine Monotherapy Struggled?
Cancer-vaccine trials have demonstrated an important paradox: a vaccine can generate tumor-specific T-cell responses without necessarily producing durable tumor control.
One explanation is the tumor microenvironment.
Vaccine-induced T cells still need to reach the tumor, recognize cancer cells and remain functional. Tumors can activate immune-checkpoint pathways, suppress antigen presentation, recruit immunosuppressive cells and expose T cells to persistent stimulation that can contribute to functional exhaustion.
This helps explain why the historical expectation that a therapeutic cancer vaccine alone would eradicate established tumors has often been disappointing.
However, these results should not be interpreted as proof that cancer-vaccine monotherapy cannot work.
We cannot separate the performance of earlier monotherapies from the technologies used to create them. Suboptimal antigen or neoantigen selection, vaccine constructs, delivery technologies, dosing and treatment schedules may all have contributed to disappointing efficacy.
Failure of a particular vaccine as monotherapy therefore does not necessarily represent failure of the monotherapy concept. It may mean that the right vaccine has not yet been tested in the right way.
Combination Therapy Strengthens the Case—but Does Not Rule Out Monotherapy
There is nevertheless strong biological logic for combining personalized cancer vaccines with other immunotherapies.
A personalized vaccine can generate and expand T cells capable of recognizing tumor-specific antigens, while checkpoint inhibitors such as anti-PD-1 therapies can help remove inhibitory signals restricting those cells.
Put simply: the vaccine can generate and expand the tumor-specific immune response; checkpoint inhibition can help create conditions in which that response remains effective.
Emerging clinical evidence supports this strategy. Individualized neoantigen vaccines combined with checkpoint inhibition have demonstrated encouraging clinical outcomes, strengthening the case for rational combination therapy.
But evidence supporting combination therapy should not automatically become evidence against monotherapy.
As vaccine technologies improve, some patients or disease settings may potentially respond to vaccination alone, while others may require checkpoint inhibitors, targeted therapies, chemotherapy or other interventions.
The future question may therefore not be “monotherapy or combination therapy?”
It may be: “What does this particular patient’s cancer require?”
Personalization should ultimately apply not only to what goes into the vaccine, but also to how that vaccine is used.
The Other Critical Variable: Time
There is another challenge: manufacturing speed.
Cancer does not wait while a personalized medicine is manufactured.
Individualized vaccine production requires tumor processing, sequencing, computational analysis, neoantigen selection, manufacturing, quality control and release. If this process takes many weeks, the tumor may progress or evolve before treatment reaches the patient.
For personalized cancer vaccines, manufacturing time is therefore not simply an operational metric.
Manufacturing time is potentially a biological variable.
A vaccine manufactured against yesterday’s tumor may not necessarily be the optimal vaccine for tomorrow’s tumor.
The successful platform must therefore solve several problems simultaneously: selecting the right neoantigens, generating effective immunity, manufacturing rapidly and determining whether monotherapy or combination treatment is appropriate.
Why Genevation Is Taking a Different Approach
At Genevation, we believe personalized cancer vaccines should be developed as an integrated therapeutic platform rather than simply an mRNA product.
Our approach connects computational biology, tumor immunology and rapid individualized manufacturing.
At its center is NeoGenAI, our computational neoantigen discovery and prioritization platform. Its objective is not simply to identify mutations or predict peptide-HLA binding, but to improve the selection of tumor-specific candidates with the potential to generate biologically meaningful immune responses.
The industry’s challenge is no longer whether we can sequence tumors and identify mutations.
We can.
The harder question is: Which mutations should actually become part of the patient’s vaccine?
Genevation is also developing a rapid, cell-free personalized mRNA manufacturing platform. Our development objective is to move from patient biopsy and sequencing through computational neoantigen selection and personalized vaccine manufacture in approximately 14 days.
Genevation has generated encouraging preclinical evidence across multiple syngeneic tumor models together with neoantigen-specific immune responses. These findings remain preclinical and require IND-enabling and clinical validation, but they provide a foundation for evaluating this integrated approach.
The Next Chapter of Precision Oncology
Personalized cancer vaccines sit at the intersection of genomics, artificial intelligence, immunology and advanced manufacturing.
The companies that ultimately lead this field may not simply be those capable of producing mRNA. They may be those capable of building an end-to-end system that converts an individual patient’s cancer biology into a clinically actionable treatment strategy.
That requires learning from previous vaccine trials rather than simply concluding that vaccines—or monotherapy—failed.
Better neoantigen selection, optimized vaccine design, rapid manufacturing and intelligent use of monotherapy or combination treatment could fundamentally change what personalized cancer vaccines can achieve.
The ultimate measure of success will not be whether we can manufacture a personalized cancer vaccine.
It will be whether we can deliver the right vaccine, with the right treatment strategy, to the right patient, at the right biological moment.